請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54215
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉仁沛 | |
dc.contributor.author | Ya-Hsuan Hsiung | en |
dc.contributor.author | 熊雅璇 | zh_TW |
dc.date.accessioned | 2021-06-16T02:45:05Z | - |
dc.date.available | 2018-07-22 | |
dc.date.copyright | 2015-07-22 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-20 | |
dc.identifier.citation | Calo-Fernandez, B. and Martinez-Hurtado, J. L. (2012) Biosimilars: company strategies to capture value from the biologic market, Pharmaceuticals. 5:1939-1408.
Chiang C., Hsiao C. F., Liu J.P. (2014) Sample size determination for individual bioequivalence inference, Plos One. 9: e109746. Chinchilli, V. M. (1996) The assessment of individual and population bioequivalence, Journal of Biopharmaceutical Statistics. 6:1-14. Chinchilli V. M., Esinhart J.D. (1996) Design and analysis of intra-subject variability in cross-over experiment, Statistics in Medicine.15:1619-1634. Chow S.C., Liu J.P. (2010a) Design and Analysis of Bioavailability and Bioequivalence Studies, 3th Ed., CRC/Chapman and Hall, Taylor and France, New York. Chow S.C., Liu J.P. (2010b) Statistical Assessment of Biosimilar Products. Journal of Biopharmaceutical Statistics. 20:10-30. Chow S.C., Yang L.Y., Starr A., Chiu S.T. (2013) Statistical methods for assessing inter-changeability of biosimilars, Statistics in Medicine 32: 442-448. EMA (2005) Guideline on Similar Biological Medicinal Products. The European Medicines Agency Evaluation of Medicines for Human Use; EMA: London, UK. EMEA/CHMP/437/04. EMA (2013) Guideline on Similar Biological Medicinal Products Containing Interferon Beta; EMA: London, UK; EMA/ CHMP/ BMWP/ 652000. FDA (2001). Guidance on Statistical Approaches to Establishing Bioequivalence, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD. FDA (2003). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products—General Considerations, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD. FDA (2012) Draft Guidance on Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, The United States Food and Drug Administration, Silver Spring, Maryland, USA. FDA (2012) Draft Guidance on Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product; FDA: Silver Spring, Maryland, USA. FDA (2012) Draft Guidance on Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; FDA: Silver Spring, Maryland, USA. Hauschke D., Steinijans V., Pigeot I. (2007) Bioequivalence studies in drug development: methods and applications. John Wiley & Sons Ltd, UK. Lawrence, S., Lahteenmaki, R. (2014) Public biotech 2013–the numbers, Nature biotechnology. 32: 626-632. Lee Y.H, Shao J., Chow S.C. (2004). Modified large-sample confidence intervals for linear combinations of variance components: extension, theory, and application. Journal of the American Statistical Association, 99, 467-478 Miller, S. (2013) The $250 Billion Potential of Biosimilars. Published on Internet: http://lab.express-scripts.com/insights/industry-updates/the-$250-billion-potential-of-biosimilars. Assessed date: 2015/03/24. Quintiles (2014) Regulatory Requirements. Published on Internet: http://www.quintiles.com/microsites/biosimilars-knowledge-connect/regulatory-requirements. Assessed date: 2015/03/17. Scheinberg, M. A. , Kay, J. (2012) The advent of biosimilar therapies in rheumatology -- 'O brave new world', Nat Rev Rheumatol. 8:430-436. The Biosimilarz Blog! (2014) Approved Biosimilars. Published on Internet: http://www.biosimilarz.com/?page_id=242. Assessed date: 2015/03/24. TFDA (2008) Guideline on the Examination and Registration of Drugs – Guideline on Biosimilar Products, Taiwan Food and Drug Administration, Taipei, Taiwan. WHO (2009) Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), World health Organization, Geneva, Switzerland. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54215 | - |
dc.description.abstract | 生物製劑是利用生命系統或生物體所製造的藥品或醫療器材,相對於具有專利的原廠生物製劑,生物相似藥品與原廠藥品具有高度相似性,由於兩者僅在臨床非活性成分上有微小的差異,在安全性、純度與效力上,無臨床上有意義的差異。因此在原廠對照生物製劑專利期限到期後,具有相同療效與安全性但價格較低之生物相似性藥品的投入,不僅能夠造福更多的病患,更能減輕全民健保的負擔。
然而,由於生物製劑的製程過程十分複雜,即使生物相似性藥品與原廠對照生物製劑僅有些微的成分不同,也可能造成臨床上顯著的差異,或引起嚴重的過敏反應。因此生物相似性藥品,相對於原廠對照生物製劑研發規模和成本較小的情況下,必須透過統計方法,以謹慎評估生物相似性藥品之安全性、純度與效力上,是否不具有臨床上顯著的差異。 互換性為其中一評估條件,當生物相似性藥品與原廠對照生物製劑,均在同一位病人上重複施用,可分別得到生物相似性藥品及原廠對照生物製劑的反應值分布,若兩分布很接近表示生物相似性藥品與原廠對照生物製劑具有互換性。本研究即嘗試以個體與處理交互作用的變異數作為互換性指標,推導出2x4交叉設計下相對應的統計推論,以評估互換性是否成立,更進一步計算互換性評估所需樣本數,最後以實例和模擬介紹所提出方法之應用。 | zh_TW |
dc.description.abstract | Biological products are defined as therapeutic agents or medical devices manufactured by living systems or living organisms. Because of the complexity of manufacturing process, biological products are costly. A Biosimilar product is approved if it is highly similar to a reference biological product which is under patent protection. So, after the expiration of the patent protects of the reference products, the biosimilar with the same therapeutically effect may get into the market and saves numerous patients who can only afford the less expensive biosimilar product than the reference one.
However, unlike the conventional chemical drug with small molecules, the biological products are composed of complex compounds such as proteins, nucleotides. Even a minor difference in clinically inactive components may cause a serious adverse effect or death. Thus, the traditional methods in evaluation for bioequivalence of a generic drug are not appropriate for evaluating biosimilar products. Therefore, stricter statistical criteria are necessary for assessment between the biosimilar drug product and the reference product. One of the requirements for biosimilar drug products stated by the United States Food and Drug Administration is that biosimilar drug products are expected to achieve the same clinical effects in any given patient as the reference biological products. Therefore, biosimilar drug product and the reference biological product are interchangeable. Interchangeability dictates that the marginal distribution of the responses from the biosimialr product and its reference are close within a pre-specified allowable limit. We propose the variance of the subject-by-formulation interaction (SBFI) as a criterion for evaluation of interchangeability. Under the two-period four-sequence (2 x 4) crossover design, we develop a statistical testing procedure based on SBFI. Simulation studies were conducted to empirically investigate the size and power of the proposed method. Sample size determination is also suggested. Numerical examples are used to illustrate the applications of the proposed method. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:45:05Z (GMT). No. of bitstreams: 1 ntu-104-R02621206-1.pdf: 1217688 bytes, checksum: 3285f00ee0747fee6ee07ffc8fdc5d75 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Chapter 1 Introduction 1
1.1 Background and Motivations 1 1.2 Biosimilar products 2 1.3 Bioequivalence, Biosimilarity and Interchangeability 4 1.4 Objectives 8 Chapter 2 Assessment for Interchangeability 15 2.1 Individual Formulation Effect 15 2.2 Subject-by-formulation interaction 17 2.3 Hypotheses Testing 18 Chapter 3 Proposed Methods 23 3.1 Study Design 23 3.2 Criteria and Hypotheses 25 3.3 The MLS Upper Confidence Bound 28 3.4 Sample Size Determination 31 Chapter 4 Numeric Examples 35 Chapter 5 Simulation Studies 40 5.1 Properties of the Hypotheses 41 5.1.1 Empirical Size 41 5.1.2 Empirical Power 42 5.2 Sample Size 44 Chapter 6 Discussion and Conclusion 63 Reference 66 Appendix A. R codes for Empirical Size 68 Appendix B. R codes for Empirical Power and Power Curve 70 Appendix C. R codes for Sample Size Determination 72 Appendix D. R codes for Analysis Based on the Proposed Methods 74 | |
dc.language.iso | en | |
dc.title | 生物相似性藥品互換性之統計評估 | zh_TW |
dc.title | Statistical Evaluation of Interchangeability of Biosimilar Drug Products | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 季瑋珠,林志榮 | |
dc.subject.keyword | 生物製劑,生物相似性藥品,互換性,個別處理效應交互作用,交叉設計,改良式大樣本方法, | zh_TW |
dc.subject.keyword | Biological product,Biosimialr product,Interchangeability,Subject-by-Formulation Interaction,Cross-over Design,Modified Large Sample Method, | en |
dc.relation.page | 75 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-07-20 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 農藝學研究所 | zh_TW |
顯示於系所單位: | 農藝學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。